News in brief

BioPorto platform validated on Qiagen’s lateral flow system


BioPorto Diagnostics and Qiagen have validated BioPorto’s generic Rapid Assay Device (gRAD) lateral flow platform on Qiagen’s ESEQuant LR3 Lateral Flow System.

The firms said combining gRAD with the ESEQuant LRS system provides a toolbox for development of lateral flow-based assays which are used in food industry and environmental testing.

They added demand for new applications in the lateral flow market space is rapidly increasing.

No specific antibodies are immobilized on the strip as part of gRAD, making testing a variety of biomarkers and labeling systems more flexible.

The generic lateral flow strip has a test line where a biotinylated capture antibody (or other biotinylated proteins) will bind and a control line.

A range of strips with fluorescence or colorimetric labels or different number of strips and lines can be analysed by the ESEQuant LR3 Lateral Flow System. 

Jan Kuhlmann Andersen, COO of BioPorto, said the combination means it has an assay development process in place to test across a variety of business segments.

With the gRAD platform BioPorto Diagnostics has the ability to offer assay developers across several industries contract development of their assay development.”

Related News

Picture: iStock

Qiagen sees ‘significant’ bioinformatics market opportunities

Neogen targets pro-active testing for pork with lateral flow assay

Neogen launches raw pork detection test

The study will focus on detection of Salmonella in ready-to-eat foods

BioDetection developing pathogen screening system with integrated sample concentration


Seegene: This will replace current RT PCR technologies

Invisible Sentinel to develop Veriflow brewPAL assay

Invisible Sentinel tastes success with assay development

SQI's sqidlite benchtop system

SQI Diagnostics to automate assay for testing pathogens in raw milk

3M Molecular Detection Assay 2 test kits

Lysis chemistry leads to shorter enrichment times for new assays – 3M

Bruker's MALDI Biotyper platform

Bruker acquires NAT assays to expand MALDI Biotyper platform

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.